UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 278

Sortiert nach

PTEN, more than the AKT pathway

Carcinogenesis (New York), 2007-07, Vol.28 (7), p.1379-1386

2007

Volltextzugriff (PDF)

Lurbinectedin synergizes with immune checkpoint blockade to generate anticancer immunity

Oncoimmunology, 2019-11, Vol.8 (11), p.e1656502-e1656502

2019

Volltextzugriff (PDF)

Vorinostat interferes with the signaling transduction pathway of T-cell receptor and synergizes with phosphoinositide-3 kinase inhibitors in cutaneous T-cell lymphoma

Haematologica (Roma), 2010-04, Vol.95 (4), p.613-621

2010

Volltextzugriff (PDF)

Specific Effects of Trabectedin and Lurbinectedin on Human Macrophage Function and Fate—Novel Insights

Cancers, 2020-10, Vol.12 (10), p.3060

2020

Volltextzugriff (PDF)

PIM2 inhibition as a rational therapeutic approach in B-cell lymphoma

Blood, 2011-11, Vol.118 (20), p.5517-5527

2011

Volltextzugriff (PDF)

Irvalec inserts into the plasma membrane causing rapid loss of integrity and necrotic cell death in tumor cells

PloS one, 2011-04, Vol.6 (4), p.e19042-e19042

2011

Volltextzugriff (PDF)

PPP1CA contributes to the senescence program induced by oncogenic Ras

Carcinogenesis (New York), 2008-03, Vol.29 (3), p.491-499

2008

Volltextzugriff (PDF)

Molecular pharmacology and antitumor activity of Zalypsis ® in several human cancer cell lines

Biochemical pharmacology, 2009-07, Vol.78 (2), p.162-170

2009

Volltextzugriff (PDF)

Characterization of the p53 response to oncogene-induced senescence

PloS one, 2008-09, Vol.3 (9), p.e3230-e3230

2008

Volltextzugriff (PDF)

MAP17 overexpression is a common characteristic of carcinomas

Carcinogenesis (New York), 2007-08, Vol.28 (8), p.1646-1652

2007

Volltextzugriff (PDF)

MAP17 enhances the malignant behavior of tumor cells through ROS increase

Carcinogenesis (New York), 2007-10, Vol.28 (10), p.2096-2104

2007

Volltextzugriff (PDF)

The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications

Current cancer drug targets, 2008-05, Vol.8 (3), p.187

2008

Volltextzugriff (PDF)

Mice expressing myrAKT1 in the mammary gland develop carcinogen-induced ER-positive mammary tumors that mimic human breast cancer

Carcinogenesis (New York), 2007-03, Vol.28 (3), p.584-594

2007

Volltextzugriff (PDF)

MAP17 inhibits Myc-induced apoptosis through PI3K/AKT pathway activation

Carcinogenesis (New York), 2007-12, Vol.28 (12), p.2443-2450

2007

Volltextzugriff (PDF)

Retraction Note: CBX7 controls the growth of normal and tumor-derived prostate cells by repressing the Ink4a/Arf locus

Oncogene, 2022-11, Vol.41 (45), p.4980-4980

2022

Volltextzugriff (PDF)

Mst1, RanBP2 and eIF4G are new markers for in vivo PI3K activation in murine and human prostate

Carcinogenesis (New York), 2007-07, Vol.28 (7), p.1418-1425

2007

Volltextzugriff (PDF)

Loss-of-function genetic screening identifies a cluster of ribosomal proteins regulating p53 function

Carcinogenesis (New York), 2008-07, Vol.29 (7), p.1343-1350

2008

Volltextzugriff (PDF)

Extreme sensitivity to Yondelis® (Trabectedin, ET-743) in low passaged sarcoma cell lines correlates with mutated p53

Journal of cellular biochemistry, 2007-02, Vol.100 (2), p.339-348

2007

Volltextzugriff (PDF)

CBX7 controls the growth of normal and tumor-derived prostate cells by repressing the Ink4a Arf locus

Oncogene, 2005-08, Vol.24 (36), p.5543-5551

2005

Volltextzugriff (PDF)

Abstract 3039: Lurbinectedin specifically targets transcription in cancer cells, triggering DNA breaks and degradation of phosphorylated Pol II

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.3039-3039

2016

Volltextzugriff (PDF)

Inhibition of phosphatidylinositol-3-kinase synergizes with gemcitabine in low-passage tumor cell lines correlating with Bax translocation to the mitochondria

Anti-cancer drugs, 2005-10, Vol.16 (9), p.977-987

2005

Volltextzugriff (PDF)

Pim 1 kinase inhibitor ETP-45299 suppresses cellular proliferation and synergizes with PI3K inhibition

Cancer letters, 2011-01, Vol.300 (2), p.145-153

2011

Volltextzugriff (PDF)

Levels of p27(kip1) determine Aplidin sensitivity

Molecular cancer therapeutics, 2007-04, Vol.6 (4), p.1310-1316

2007

Volltextzugriff (PDF)

Abstract 1165: Plitidepsin targets the moonlighting functions of eEF1A2 in cancer cells

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.1165-1165

2017

Volltextzugriff (PDF)

Abstract 2906: eEF1A2 interacts with and inhibits PKR to enhance cancer cell survival

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.2906-2906

2018

Volltextzugriff (PDF)

1 – 25 von 278

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(254)
Mit Volltextzugriff
(261)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

PTEN, more than the AKT pathway

Lurbinectedin synergizes with immune checkpoint blockade to generate anticancer immunity

Vorinostat interferes with the signaling transduction pathway of T-cell receptor and synergizes with phosphoinositide-3 kinase inhibitors in cutaneous T-cell lymphoma

Specific Effects of Trabectedin and Lurbinectedin on Human Macrophage Function and Fate—Novel Insights

PIM2 inhibition as a rational therapeutic approach in B-cell lymphoma

Irvalec inserts into the plasma membrane causing rapid loss of integrity and necrotic cell death in tumor cells

PPP1CA contributes to the senescence program induced by oncogenic Ras

Molecular pharmacology and antitumor activity of Zalypsis ® in several human cancer cell lines

Characterization of the p53 response to oncogene-induced senescence

MAP17 overexpression is a common characteristic of carcinomas

MAP17 enhances the malignant behavior of tumor cells through ROS increase

The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications

Mice expressing myrAKT1 in the mammary gland develop carcinogen-induced ER-positive mammary tumors that mimic human breast cancer

MAP17 inhibits Myc-induced apoptosis through PI3K/AKT pathway activation

Retraction Note: CBX7 controls the growth of normal and tumor-derived prostate cells by repressing the Ink4a/Arf locus

Mst1, RanBP2 and eIF4G are new markers for in vivo PI3K activation in murine and human prostate

Loss-of-function genetic screening identifies a cluster of ribosomal proteins regulating p53 function

Extreme sensitivity to Yondelis® (Trabectedin, ET-743) in low passaged sarcoma cell lines correlates with mutated p53

CBX7 controls the growth of normal and tumor-derived prostate cells by repressing the Ink4a Arf locus

Abstract 3039: Lurbinectedin specifically targets transcription in cancer cells, triggering DNA breaks and degradation of phosphorylated Pol II

Inhibition of phosphatidylinositol-3-kinase synergizes with gemcitabine in low-passage tumor cell lines correlating with Bax translocation to the mitochondria

Pim 1 kinase inhibitor ETP-45299 suppresses cellular proliferation and synergizes with PI3K inhibition

Levels of p27(kip1) determine Aplidin sensitivity

Abstract 1165: Plitidepsin targets the moonlighting functions of eEF1A2 in cancer cells

Abstract 2906: eEF1A2 interacts with and inhibits PKR to enhance cancer cell survival

Suchergebnisse filtern